Scientists discover ibogaine resets the brain's ability to form new connections like a juvenile brain does. This finding is so interesting that researchers and funders will support at least 5 major published studies and create 2 dedicated research groups to explore it — even if the FDA never approves ibogaine as medicine. This matters because it opens a whole new way to think about how ibogaine works, separate from whether it's actually safe to use as treatment.
The juvenile-like plasticity finding is a paradigm-level result that reframes ibogaine as a 'plasticity reset tool' fundable as basic neuroscience regardless of FDA decisions. However, '5 major studies' and '2 consortia' are specific thresholds that depend on funding cycles, publication timelines, and whether the initial findings replicate. Basic science interest is credible; hitting both numerical thresholds by 2027 is less certain. Confidence trimmed from 0.85 to account for the specificity of dual criteria.